Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses the impact biosimilars could make in community oncology.
Absolutely, they already have. So what we’re seeing in the biosimilar front is actually a greater adoption than most folks thought initially. And for the non—supportive chemotherapy agents like Avastin, Herceptin, Rituxan, you know, we were thinking it might be a 10% adoption right away. It's looking more like it's 15 to 20%. So I think you can see that trend continue. Biosimilars are going to be here to stay in my opinion, and it's going to be a great opportunity for community oncology.